Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

37 questions · 38 findings · 20 reviews · Headline outcomes only

No studies found 15 · 39.5%GRADE not reported 2 · 5.3%Very low 8 · 21.1%Low 7 · 18.4%Moderate 3 · 7.9%High 3 · 7.9%

Next‐generation ALK inhibitor vs crizotinib

Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

It is very uncertain whether next‐generation ALK inhibitor changes health‐related quality of life: time to deterioration in composite… compared with crizotinib (very low certainty).

1 finding from 1 review

ALK inhibitor vs any cytotoxic chemotherapy

Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).

1 finding from 1 review